Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Bevacizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Bevacizumab as a study intervention. Browse Bevacizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1373
Shown on this page
12
Current sort
Recently updated
Therapy scope
Bevacizumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Bevacizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 337–348 of 1,373 matching trials for Bevacizumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1Phase 2 Interventional

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

NCT01478178
View directory record Official record
Conditions
Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
Interventions
VAL-083 (Dianhydrogalactitol)
Drug
Lead sponsor
Kintara Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

NCT03977467
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Solid Tumor
Interventions
Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Terminated Early Phase 1 Interventional

Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6

NCT04074785
View directory record Official record
Conditions
GBM, Glioblastoma, Brain Tumor, Brain Tumor, Recurrent
Interventions
Abemaciclib, Bevacizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

NCT01931098
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms, Central Nervous System Neoplasms
Interventions
topotecan, pazopanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

NCT02681549
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
Interventions
Pembrolizumab plus Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Bevacizumab for Recurrent Ependymoma

NCT01295944
View directory record Official record
Conditions
Ependymoma, Anaplastic Ependymoma
Interventions
Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Terminated Not applicable Interventional

Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

NCT03698162
View directory record Official record
Conditions
Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Bevacizumab Injection
Other
Lead sponsor
University of Southern California
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of DKN-01 in Colorectal Cancer

NCT05480306
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic
Interventions
DKN-01, FOLFIRI, Bevacizumab, FOLFOX
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Cape Coral, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT03326193
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Bevacizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Terminated Phase 2 Interventional Results available

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

NCT03295396
View directory record Official record
Conditions
Glioma
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

NCT03574779
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

NCT02436993
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Carboplatin, Paclitaxel, Bevacizumab, Trastuzumab, Pertuzumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 30, 2026, 2:51 AM EDT

About this Bevacizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Bevacizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bevacizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Bevacizumab.